Non-speculum sampling approaches for cervical screening in older women: randomised controlled trial.


Journal

The British journal of general practice : the journal of the Royal College of General Practitioners
ISSN: 1478-5242
Titre abrégé: Br J Gen Pract
Pays: England
ID NLM: 9005323

Informations de publication

Date de publication:
01 2022
Historique:
received: 08 06 2021
accepted: 25 08 2021
entrez: 1 1 2022
pubmed: 2 1 2022
medline: 9 3 2022
Statut: epublish

Résumé

Cervical cancer disproportionately affects women ≥65 years, especially those not screened regularly. Speculum use is a key barrier. To assess if offering non-speculum clinician-taken sampling and self-sampling increases uptake for lapsed attenders aged 50-64 years. Pragmatic randomised control trial conducted at 10 general practices in East London, UK. Participants were 784 women aged 50-64 years, last screened 6-15 years before randomisation. Intervention participants received a letter offering the choice of non-speculum clinician- or self-sampling. Control participants received usual care. The main outcome measure was uptake within 4 months. Screening uptake 4 months after randomisation was significantly higher in the intervention arm: 20.4% ( Offering non-speculum clinician-taken sampling and self-sampling substantially increases uptake in older lapsed attendee women. Non-speculum clinician sampling appeals to women who dislike the speculum but still prefer a clinician to take their sample. Providing a choice of screening modality may be important for optimising cervical screening uptake.

Sections du résumé

BACKGROUND
Cervical cancer disproportionately affects women ≥65 years, especially those not screened regularly. Speculum use is a key barrier.
AIM
To assess if offering non-speculum clinician-taken sampling and self-sampling increases uptake for lapsed attenders aged 50-64 years.
DESIGN AND SETTING
Pragmatic randomised control trial conducted at 10 general practices in East London, UK.
METHOD
Participants were 784 women aged 50-64 years, last screened 6-15 years before randomisation. Intervention participants received a letter offering the choice of non-speculum clinician- or self-sampling. Control participants received usual care. The main outcome measure was uptake within 4 months.
RESULTS
Screening uptake 4 months after randomisation was significantly higher in the intervention arm: 20.4% (
CONCLUSION
Offering non-speculum clinician-taken sampling and self-sampling substantially increases uptake in older lapsed attendee women. Non-speculum clinician sampling appeals to women who dislike the speculum but still prefer a clinician to take their sample. Providing a choice of screening modality may be important for optimising cervical screening uptake.

Identifiants

pubmed: 34972808
pii: BJGP.2021.0350
doi: 10.3399/BJGP.2021.0350
pmc: PMC8714504
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e26-e33

Subventions

Organisme : Cancer Research UK
ID : C16499/A21716
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C7492/A17219
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Authors.

Références

J Womens Health Gend Based Med. 2002 Apr;11(3):265-75
pubmed: 11988136
JMIR Cancer. 2020 Oct 29;6(2):e21697
pubmed: 33027039
Sex Transm Infect. 2017 Feb;93(1):56-61
pubmed: 28100761
J Med Screen. 2018 Dec;25(4):205-210
pubmed: 29439604
J Med Screen. 2018 Jun;25(2):88-98
pubmed: 28530513
BJOG. 2012 Jan;119(1):26-32
pubmed: 21668764
Prev Med. 2017 Aug;101:60-66
pubmed: 28502577
N Engl J Med. 1979 May 31;300(22):1242-5
pubmed: 431682
Qual Prim Care. 2012;20(2):115-23
pubmed: 22824564
J Med Screen. 2009;16(4):193-8
pubmed: 20054094
Lancet Public Health. 2018 Jan;3(1):e34-e43
pubmed: 29307386
J Med Screen. 2015 Mar;22(1):28-37
pubmed: 25403717
Prev Med. 2020 Oct;139:106170
pubmed: 32610059
Acta Obstet Gynecol Scand. 2019 Aug;98(8):1063-1069
pubmed: 30868579
PLoS Med. 2014 Jan;11(1):e1001585
pubmed: 24453946
Cochrane Database Syst Rev. 2011 May 11;(5):CD002834
pubmed: 21563135
BMC Womens Health. 2019 Feb 26;19(1):38
pubmed: 30808349
J Med Screen. 2004;11(2):85-8
pubmed: 15153323
Gynecol Oncol Rep. 2018 May 22;25:48-51
pubmed: 30023421
PLoS Med. 2017 Oct 24;14(10):e1002414
pubmed: 29065127
Br J Cancer. 2011 Mar 15;104(6):915-20
pubmed: 21343937
J Clin Pathol. 2002 Jun;55(6):435-9
pubmed: 12037026
Lancet. 2017 Apr 1;389(10076):1323-1335
pubmed: 28236464
J Med Screen. 2017 Mar;24(1):43-49
pubmed: 27235844
J Med Screen. 2009;16(4):199-204
pubmed: 20054095
J Psychosom Obstet Gynaecol. 2008 Dec;29(4):251-7
pubmed: 18608824
J Med Screen. 2017 Sep;24(3):127-145
pubmed: 27754937
Anticancer Res. 2019 Jan;39(1):381-386
pubmed: 30591484

Auteurs

Rebecca Landy (R)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, US.

Tony Hollingworth (T)

Whipps Cross University Hospital, Barts Health NHS Trust, London.

Jo Waller (J)

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London.

Laura Av Marlow (LA)

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London.

Jane Rigney (J)

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London.

Thomas Round (T)

School of Population Health and Environmental Sciences, King's College London, London and National Cancer Analysis and Registration Service, Public Health England.

Peter D Sasieni (PD)

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London.

Anita Ww Lim (AW)

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH